



Attorneys at Law

RECEIVED
CENTRAL FAX CENTER

SEP 25 2006

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
t 404 815 6500 f 404 815 6555
www.KilpatrickStockton.com

September 25, 2006

direct dial 404 815 6473
direct fax 404-541-3435
ZDoddridge@KilpatrickStockton.co**FAX**

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Jana A. Hines Group 1645	571-273-8300	United States Patent and Trademark Office Washington, D.C.

Zara A. Doddridge, Ph.D.

FROM

5

PAGES (WITH COVER)

0901

REFERENCE NO

45738-296417

CLIENT/MATTER NO.

PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.**CONFIDENTIALITY NOTE:**

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

In re Application of Muldoon et al.
U.S. Patent Application No. 10/789,433
Filed: February 27, 2004

Papers enclosed:

Amendment Transmittal
Response to Election/Restriction Requirement

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME: _____

COMPLETED BY: _____

JOB CODE _____

ATLANTA AUGUSTA CHARLOTTE LONDON NEW YORK RALEIGH STOCKHOLM WASHINGTON WINSTON-SALEM

US20060909470.1

PATENTS

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No. 19596-0571 (45738-296417)

MULDOON et al.

Serial No. 10/789,433

Filed: February 27, 2004

For: COMPOSITIONS AND METHODS FOR THE SPECIFIC DETECTION OF MAMMALIAN
MUSCLE PROTEINRECEIVED
CENTRAL FAX CENTER
SEP 25 2006Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a paper in the above-identified application.

- ☒ Response to Election/Restriction Requirement.
☒ Applicant claims small entity status.
☒ No additional fee is required.
☐ The additional fee is calculated as shown below:

					SMALL ENTITY	OTHER THAN SMALL ENTITY		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEB	RATE	ADDIT. FEE
TOTAL	19	MINUS	20 =	0	x25	\$	x50	\$
INDEP.	4	MINUS	4 =	0	x100	\$	x200	\$
FIRST PRESENTATION OF								
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+180	\$	+360	\$
TOTAL					ADDITIONAL FEE		\$ 0	
							\$	

- ☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855.

I hereby certify that this correspondence is being sent to the
 United States Patent and Trademark Office via facsimile transmission
 To 571-273-8300, attention Centralized Fax Department on
 September 25, 2006

Z. Doddridge
 Zara A. Doddridge, Ph.D. - Reg. No. 59,098

KILPATRICK STOCKTON LLP
 1100 Peachtree Street
 Suite 2800
 Atlanta, Georgia 30309-4530
 Telephone: 404/815-6500

By: Z. Doddridge
 Zara A. Doddridge, Ph.D. - Reg. No. 59,098

ATLL1302 1292571

ATTORNEY DOCKET NO. 45738-296417

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MULDOON ET AL.

Serial No. 10/789,433

Filed: FEBRUARY 27, 2004

For: COMPOSITIONS AND METHODS FOR
THE SPECIFIC DETECTION OF
MAMMALIAN MUSCLE PROTEINS

Art Unit: 1645

Examiner: Hines, Jana. A

RECEIVED
CENTRAL FAX CENTER
SEP 25 2006RESPONSE TO ELECTION/RESTRICTION REQUIREMENTMail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In the Election/Restriction Requirement mailed August 24, 2006, the Examiner required restriction of the above-identified patent application to one of the following patentably distinct inventions:

Group I: Claims 1-8 directed to a ligand specific for mammalian troponin, wherein the ligand comprises a molecule that binds to a mammalian molecule, but not an avian troponin molecule, wherein the ligand is an antibody produced by immunizing an animal with a peptide having one of the amino acid sequences selected from the group consisting of SEQ ID NO: 2-6, 9-13 and 15-35;

Group II: Claim 9 directed to an antigen for the production of an antibody specific for mammalian troponin molecule, wherein the antigen comprises an isolated peptide having one

I hereby certify that this correspondence is being sent to the United States Patent and Trademark Office via facsimile transmission to 571-273-8300, attention Centralized Fax Department on September 25, 2006.



Zara A. Doddridge, Ph.D. - Registration No: 59,098

US2003 920044 1

*Response to Restriction Requirement**Serial No. 10/789,433**Page 2*

of the amino acid sequences selected from the group consisting of SEQ ID NO: 2-6, 9-13 and 15-35;

Group III: Claims 10-18 directed to an assay for detecting a mammalian troponin molecule in a sample, the assay comprising: a reaction step and a detecting step, wherein the ligand is an antibody produced by immunizing an animal with a peptide having one of the amino acid sequences selected from the group consisting of SEQ ID NO: 2-6, 9-13 and 15-35;

Group IV: Claim 19 directed to a method of making an antibody that is specific for a mammalian troponin molecule and not specific for an avian troponin molecule, comprising administering to an animal an immunogenic amount of a peptide having one of the amino acid sequences selected from the group consisting of SEQ ID NO: 2-6, 9-13 and 15-35.

In addition, the Examiner requested election of one specific sequence for the associated Group election.

In response to the Restriction Requirement, Applicants elect Group III directed to Claims 10-18. Furthermore, Applicants elect with traverse, amino acid sequence SEQ ID NO: 2 as the sequence associated with the group election.

Applicants respectfully submit amino acid sequences SEQ ID NO: 2-6, 9-13 and 15-35 share physical and functional characteristics. In Group III, each amino acid sequence may be used to immunize an animal, which in turn elicits an immune response. Clearly, all amino acids sequences listed in the Markush Group are related because they are amino acid sequences. Additionally, each amino acid must functionally elicit an immune response (production of antibodies) when administered to an animal. Applicants respectfully submit that each amino acid sequence listed in Group III (Claims 10-18) share a physical and functional characteristic and should therefore be examined on their merit.

Response to Restriction Requirement
Serial No. 10/789,433
Page 3

No additional fees are believed due; however the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account number 11-0855.

Respectfully submitted,



By: Zara A. Doddridge, Ph.D.
Registration No: 59,098

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our File: 45738-296417

UNZINLO 9450104 1